Acriptega Tablet (Dolutegravir (50mg) + Lamivudine (300mg) + Tenofovir disoproxil fumarate (300mg))

Acriptega Tablet is a fixed dose combination of three antiviral drugs. It is composed of three salts, Dolutegravir (50mg), Lamivudine (300mg) and Tenofovir disoproxil fumarate (300mg). This antiviral medicine is used to fight against Human Immunodeficiency Virus (HIV) that can cause AIDS at later stages. Dolutegravir is an integrase strand transfer inhibitor that blocks HIV integrase enzyme.

Thus, preventing integration of viral DNA into host's genome. Lamivudine is a nucleoside reverse transcriptase inhibitor that mimics the natural nucleoside and get incorporated into virus DNA. As a result, inhibiting virus replication due to default structure. Tenofovir disoproxil fumarate inhibits the reverse transcriptase enzyme by acting as DNA chain terminator. Thus preventing conversion of viral DNA to human DNA.

HIV

Acriptega Tablet cause multiple side effects like any other chemical based medication. Side effects may range from mild to extreme. Any persistent, worsening, or unusual symptoms should be immediately reported to the doctor.
Common Side Effects of Acriptega Tablet
● Diziness
● Headache
● Nausea
● Vomiting
● Fatigue
● Weakness
● Cough
● Skin Rashes
● Congestion
● Muscle or Joint Pain
● Low Phosphate in Blood
Less Common Side Effects of Acriptega Tablet
● Severe Allergic Reactions
● Extreme Mood Changes such as Depression, Anxiety, Suicidal thoughts etc.
● Liver Problems
● Liver Damage
● Kidney Problems
● Lactic Acidosis
● Blood Problems
● Low Bone Density

The usual dosage of Acriptega Tablet is one tablet daily. It should be swallowed whole with the help of water. Do not crush, chew, bite or break the tablet. For personalized dosage and treatment duration, consult your doctor. Take the medicine at the same time every day to maintain consistent drug levels.

● Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., ... & Perea, R. T. (2019). Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet, 393(10167), 143-155.
● Deng, L., Li, C., Chen, P., Luo, X., Zheng, X., Zhou, L., ... & Hong, Z. (2022). Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection. BMC infectious diseases, 22(1), 17.
● Venter, W. D., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., ... & Hill, A. (2019). Dolutegravir plus two different prodrugs of tenofovir to treat HIV. New England Journal of Medicine, 381(9), 803-815.
● Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., ... & Whalen, F. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet, 397(10281), 1276-1292.